Compare ABX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABX | ARDX |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.0M | 996.8M |
| IPO Year | 2020 | 2014 |
| Metric | ABX | ARDX |
|---|---|---|
| Price | $9.59 | $3.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.50 | ★ $15.14 |
| AVG Volume (30 Days) | 558.4K | ★ 4.7M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 205.88 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $235,237,636.00 | $2,607,000.00 |
| Revenue This Year | $19.18 | $37.75 |
| Revenue Next Year | $14.60 | $34.24 |
| P/E Ratio | $69.00 | ★ N/A |
| Revenue Growth | ★ 110.18 | N/A |
| 52 Week Low | $7.18 | $3.86 |
| 52 Week High | $12.44 | $8.40 |
| Indicator | ABX | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 24.09 |
| Support Level | $8.35 | N/A |
| Resistance Level | $9.75 | $6.16 |
| Average True Range (ATR) | 0.50 | 0.19 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 44.94 | 1.46 |
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The company operates through four distinct yet complementary divisions: Abacus Life Solutions, Abacus Asset Group, Abacus Intel, and Abacus Wealth Advisors. It operates through three reportable segments, Asset management, Life solutions, and Technology services. It derives the majority revenue from Life solutions segment that generates revenues by buying, selling, and trading policies, and maintaining policies until receipt of death benefits. It also generates revenue by originating life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.